中国药房2024，Vol.35Issue(8)：1016-1022,7.DOI:10.6039/j.issn.1001-0408.2024.08.21
中药调节微RNA干预食管癌的机制研究进展
Research progress on the mechanism of traditional Chinese medicine intervening in esophageal cancer by microRNA regulation
摘要
Abstract
Esophageal cancer(EC)is a common malignant tumor of the digestive system with an extremely poor prognosis.MicroRNA(miRNA)is an important regulator in tumor occurrence and development,and can participate in malignant biological behaviors such as tumor cell proliferation,invasion,metastasis and apoptosis.Traditional Chinese medicine has the characteristics of accurate curative effects,wide range of effects,and few side effects.The review uses miRNA as the entry point to systematically elaborate on the mechanism of traditional Chinese medicine-mediated miRNA intervening in EC.The results showed that active ingredients of traditional Chinese medicine(including curcumin,Tussilago farfara polysaccharides,Atractylodes macrocephala polysaccharides and ophiopogonin B)and Dougen guanshitong oral liquid could up-regulate the expressions of miRNAs such as miRNA-532-3p(miR-532-3p),miR-551b-3p,miR-99a,miR-34a,miR-199a-3p and miR-377;and the active ingredients/parts of traditional Chinese medicine(including chrysin and Actinidia arguta extract),and Chinese herbal formulas(including Chaihu shugan san combined with Xuanfu daizhe decoction and Modified jupi zhuru decoction)could down-regulate the expressions of miRNAs such as miR-199a-3p,miR-451 and miR-21,which could regulate the expressions of signaling pathways(phosphoinositide 3-kinase/protein kinase B,etc.)or their downstream protein(zinc-finger and homeobox protein 1,etc.)or enzymes(thymidine kinase-1,etc.),inhibit the proliferation,invasion and metastasis of EC cells and induce apoptosis,thereby ultimately achieving the purpose of preventing the disease from aggravating.关键词
中药/食管癌/微RNA/信号通路/靶基因Key words
traditional Chinese medicine/esophageal cancer/microRNA/signaling pathway/target genes分类
医药卫生引用本文复制引用
沈智文,黎丽群,徐明瑶,刘鑫,黄静,张晓宁,尹嘉琪,谢胜..中药调节微RNA干预食管癌的机制研究进展[J].中国药房,2024,35(8):1016-1022,7.基金项目
国家中医药管理局岐黄学者培养项目(No.国中医药人教函[2021]203号) （No.国中医药人教函[2021]203号）
广西重点研发计划(No.桂科AB23026098) （No.桂科AB23026098）
广西中医药大学B类"桂派中医药传承创新团队"(No.2022B001) （No.2022B001）
